We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-0.86%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$1.19B
AUM Growth
-$288M
Cap. Flow
-$155M
Cap. Flow %
-13.04%
Top 10 Hldgs %
42.35%
Holding
170
New
36
Increased
27
Reduced
26
Closed
54

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$49M
2
LLY icon
Eli Lilly
LLY
+$41.1M
3
ABBV icon
AbbVie
ABBV
+$26.3M
4
PANW icon
Palo Alto Networks
PANW
+$13.1M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$11.8M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$60.1M
2
JNJ icon
Johnson & Johnson
JNJ
+$28.4M
3
GNRC icon
Generac Holdings
GNRC
+$14.3M
4
LPSN icon
LivePerson
LPSN
+$14.2M
5
AMZN icon
Amazon
AMZN
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 63.14%
2 Technology 10.82%
3 Industrials 3.99%
4 Financials 3.13%
5 Communication Services 1.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
51
Celldex Therapeutics
CLDX
$2.99B
$7.04M 0.59%
+130,330
New +$6.12M
AFMD
52
DELISTED
Affimed
AFMD
$6.91M 0.58%
111,762
-15,908
-12% -$1.05M
BLSA
53
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$6.88M 0.58%
687,900
– –
MRUS
54
DELISTED
Merus
MRUS
$6.81M 0.57%
309,427
+22,921
+8% +$492K
VRNT
55
DELISTED
Verint Systems
VRNT
$6.72M 0.56%
150,000
– –
TEAD
56
Teads Holding Co
TEAD
$68.7M
$6.38M 0.54%
+431,194
New +$7.6M
BCAB icon
57
BioAtla
BCAB
$5.46M
$6.31M 0.53%
+4,286
New +$8.35M
ZEN
58
DELISTED
ZENDESK INC
ZEN
$6.28M 0.53%
+53,910
New +$6.96M
RACB
59
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$5.91M 0.5%
600,000
– –
XENE icon
60
Xenon Pharmaceuticals
XENE
$6.06B
$5.71M 0.48%
373,510
+97,380
+35% +$1.69M
PNT
61
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
$5.68M 0.48%
739,190
-270,307
-27% -$2.47M
PMVP icon
62
PMV Pharmaceuticals
PMVP
$59.2M
$5.68M 0.48%
190,525
+106,451
+127% +$3.4M
STRO icon
63
Sutro Biopharma
STRO
$401M
$5.57M 0.47%
29,483
– –
QURE icon
64
uniQure
QURE
$3.03B
$5.51M 0.46%
172,000
– –
CALX icon
65
Calix
CALX
$2.26B
$5.2M 0.44%
+105,290
New +$4.86M
ALLT icon
66
Allot
ALLT
$372M
$5.07M 0.43%
341,067
+64,880
+23% +$1.1M
NAUT icon
67
Nautilus Biotechnolgy
NAUT
$124M
$4.91M 0.41%
800,000
– –
CRBU icon
68
Caribou Biosciences
CRBU
$145M
$4.77M 0.4%
+200,000
New +$4.89M
FOLD
69
DELISTED
Amicus Therapeutics
FOLD
$4.69M 0.39%
+491,159
New +$5.02M
PTGX icon
70
Protagonist Therapeutics
PTGX
$8.79B
$4.61M 0.39%
260,379
-42,586
-14% -$1.82M
PTGX icon
71
CALL
Protagonist Therapeutics
PTGX
$8.79B
$4.43M 0.37%
+250,000
New +$10.7M
VRNA
72
DELISTED
Verona Pharma
VRNA
$4.39M 0.37%
801,256
– –
IS
73
DELISTED
ironSource Ltd.
IS
$3.99M 0.34%
+367,070
New +$3.64M
ALGS icon
74
Aligos Therapeutics
ALGS
$26.2M
$3.87M 0.32%
+9,968
New +$3.94M
DVAX
75
DELISTED
Dynavax Technologies
DVAX
$3.82M 0.32%
+198,880
New +$2.64M
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sphera Funds Management held 170 positions worth $1.19B, down 19% from $1.48B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management withdrew a net $155M in Q3 2021, closing 54 positions and reducing 26 holdings. Its most notable exit was Merck, an estimated $60.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 55% a quarter earlier, followed by Technology and Industrials.

Against the trend, Sphera Funds Management opened a new position in Pfizer worth $47.6M.

  • Sphera Funds Management's largest Q3 2021 buy was Pfizer: 1,106,528 shares worth $47.6M.
  • Sphera Funds Management added most to Eli Lilly in Q3 2021, an estimated $41.1M increase.
  • Sphera Funds Management's biggest Q3 2021 reduction was Johnson & Johnson, cutting an estimated $28.4M.
  • Sphera Funds Management fully exited Merck in Q3 2021, selling an estimated $60.1M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $1.19B portfolio in Q3 2021.
  • Sphera Funds Management opened 36 new positions and closed 54 in Q3 2021.
  • Sphera Funds Management's portfolio value fell 19% quarter-over-quarter to $1.19B.

Based on Sphera Funds Management's 13F filing for Q3 2021, filed 15 Nov 2021.